GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Gross Profit

Parmax Pharma (BOM:540359) Gross Profit : ₹34.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Parmax Pharma Gross Profit?

Parmax Pharma's gross profit for the three months ended in Dec. 2024 was ₹17.3 Mil. Parmax Pharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was ₹34.0 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Parmax Pharma's gross profit for the three months ended in Dec. 2024 was ₹17.3 Mil. Parmax Pharma's Revenue for the three months ended in Dec. 2024 was ₹62.8 Mil. Therefore, Parmax Pharma's Gross Margin % for the quarter that ended in Dec. 2024 was 27.50%.

Parmax Pharma had a gross margin of 27.50% for the quarter that ended in Dec. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Parmax Pharma was 42.73%. The lowest was 7.76%. And the median was 33.43%.

Warning Sign:

Parmax Pharma Ltd gross margin has been in long-term decline. The average rate of decline per year is -16.2%.


Parmax Pharma Gross Profit Historical Data

The historical data trend for Parmax Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parmax Pharma Gross Profit Chart

Parmax Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.24 87.60 77.17 65.91 8.57

Parmax Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.03 -21.50 19.51 18.73 17.28

Competitive Comparison of Parmax Pharma's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parmax Pharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Parmax Pharma's Gross Profit falls into.


;
;

Parmax Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Parmax Pharma's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=110.53 - 101.957
=8.6

Parmax Pharma's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=62.844 - 45.561
=17.3

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹34.0 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Parmax Pharma's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=17.3 / 62.844
=27.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Parmax Pharma  (BOM:540359) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Parmax Pharma had a gross margin of 27.50% for the quarter that ended in Dec. 2024 => Competition eroding margins


Parmax Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Parmax Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Parmax Pharma Business Description

Traded in Other Exchanges
N/A
Address
Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.

Parmax Pharma Headlines

No Headlines